Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Caroline Shamu
Harvard Medical School, Department: Biology
Should you be removed from our database? Contact us at [email protected]. Read more below.
Merrimack Pharmaceuticals, Inc.
Payment for services (e.g., consulting fees, honoraria, paid authorship)
A potential conflict arises from ongoing scientific collaborations with Merrimack scientists on:
• Drug-ligand responses in cancer cell lines including those from breast and other tissue
• Drug-ligand responses in non-transformed cell lines and some primary cells
• Study of some cell death receptors
• Collaboration on therapeutic antibodies from third parties
The Sorger laboratory, however, does not use or study Merrimack proprietary drugs and compounds.
The HMS Laboratory of Systems Pharmacology
The computational biologists, physician-scientists and pharmacologists in the Laboratory of Systems Pharmacology will apply a combined measure-model approach to understanding the mechanisms of action of therapeutic drugs in multiple disease areas. They will develop and apply new tools to (i) investigate the factors that determine the therapeutic index of drugs at a single cell level and in tissues (ii) apply knowledge of cellulr networks to develop a rational approach to combination therapy (iii) identify and qualify new drug targets for significant unmet medical needs. Success with our approach will advance personalized medicine and reduce the frequency of late-stage failure in drug discovery, thereby reducing the cost of new medicines.
Filed on October 15, 2014.
Tell us what you know about Caroline Shamu's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Other search results for: “Caroline Shamu”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Caroline Shamu | Harvard Medical School | Conflict of Interest | Merrimack Pharmaceuticals, Inc. | $200,000 - $249,999 |
| Caroline Shamu | Harvard Medical School | Conflict of Interest | Merrimack Pharmaceuticals, Inc. | $10,000 - $19,999 |
| Caroline Shamu | Harvard Medical School | Conflict of Interest | Merrimack Pharmaceuticals, Inc. | $0 - $4,999 |
| Caroline Shamu | Harvard Medical School | Conflict of Interest | Merrimack Pharmaceuticals, Inc. | $200,000 - $249,999 |
| Caroline Shamu | Harvard Medical School | Conflict of Interest | Merrimack Pharmaceuticals, Inc. | $0 - $4,999 |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.